We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Forma Therapeutics Holdings Inc (FMTX) USD0.001

Sell:$6.71 Buy:$6.74 Change: $0.29 (4.50%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Change: $0.29 (4.50%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
Change: $0.29 (4.50%)
Market closed |  Prices as at close on 17 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.

Contact details

300 North Beacon Street, Suite 501
United States
+1 (617) 6791970

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$308.34 million
Shares in issue:
47.80 million
United States
US dollar

Key personnel

  • Frank Lee
    President, Chief Executive Officer, Director
  • Todd Shegog
    Chief Financial Officer, Senior Vice President
  • Mary Wadlinger
    Chief Human Resource Officer, Senior Vice President - Corporate Affairs
  • David Cook
    Senior Vice President, Chief Scientific Officer
  • Jeannette Potts
    Senior Vice President, General Counsel & Corporate Secretary
  • Patrick Kelly
    Senior Vice President, Chief Medical Officer
  • John Bishop
    Chief Technology Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.